Reconsideration is requested.

Claims 38, 39, 41-62, 65, 68 and 69 are pending. Claims 1-37, 40, 63, 64, 66

and 67 have been canceled, without prejudice. Claim 69 has been added and reads on

non-elected subject matter. No new matter has been added

Rejoinder and allowance of any claim defining a method of making and/or using

a product defined by an allowable claim, at an appropriate time, are requested.

Clarification is requested regarding the claims "withdrawn" from consideration.

Specifically, page 1 of the Office Action dated August 22, 2008, states that claims 61,

62 and 68 have been withdrawn from consideration. Page 2 of the Office Action states

that "Claims 62 and 68 are withdrawn as being drawn to a non-elected Group." Further,

page 3 of the Office Action states that "Claims 41, 43, 45, 49-55, 57, 59-62, and 66 are

withdrawn as being drawn to a non-examined species."

Claims 38-41, 44, 47, 52-54, 58, 59 and 61-68 read on elected species of

compound 29, which has been found free of the art of record.

While a variety of claims have been indicated as being "withdrawn", claims 38-60

and 63-67 have been examined and rejected in § 9. of the Office Action; claims 38-67

have been examined and rejected in § 10. of the Office Action; claims 38-67 have been

examined and rejected in § 12. of the Office Action; claims 38-40, 42. 44. 46-48. 56. 58.

63-65 and 67 have been examined and rejected in § 17. of the Office Action; claims 38,

61 and 62 have been examined and provisionally rejected in § 21. of the Office Action;

- 16 -

1408497

NAJIB et al Appl. No. 10/520,078 Monday, November 24, 2008

Atty. Ref.: 3665-126

AMENDMENT

consideration.

claims 38, 39, 61 and 62 have been examined and provisionally rejected in § 22. of the

Office Action; and claim 38 has been rejected in § 24. of the Office Action.

As claims 62 and 68 are not believed to read on the elected species, which the Examiner has found to be free of the art, the applicants have indicated above the status of claims 62 and 68 as having been withdrawn. Clarification is requested however in the Examiner's next Action as to the claims which have been withdrawn from

Claims 62 and 68 have been indicated above as having been withdrawn from consideration, even though claim 62 has been rejected in the Office Action of August 22, 2008. Claim 69 has been added. No new matter has been added.

The Examiner's acknowledgement that the elected species has been found free of the art is noted with appreciation. The Examiner has broadened the search to include the additional substituents noted on page 2 of the Office Action.

Further clarification is requested regarding the Examiner's further search however as the Office Action states the "Examiner moved onto the next derivative of formula I, 4'-carboxyethoxy-4-sulphocalchone." The applicants believe however that this compound is not comprised by formula (I). Specifically, as stated by the Examiner, this compound presents $X_4 = SO_3H$. The applicants submit that X_4 according to the invention however cannot be such group. According to the invention, X_4 represents an halogen atom, G4R4 or R4, wherein G4 is oxygen or sulphur atom and R4 is a hydrogen atom or an alkyl group substituted or not by a substituent which is part of group 1 or group 2, and group 2 can be SO_3H . From this definition, the applicants do

NAJIB et al Appl. No. 10/520,078

Atty. Ref.: 3665-126

Monday, November 24, 2008

AMENDMENT

not understand how $X_4\ \text{can}\ \text{be}\ \text{SO}_3\text{H}.$ Clarification is requested therefore as to whether

the Examiner has extended his search to unclaimed compounds.

A new non-final Office Action is requested clarifying the status of the claims, the

search and the scope of further examination beyond the elected species to include

further claimed subject matter.

The objection to claims 38 and 39 is obviated by the above amendments.

Withdrawal of the objections is requested.

To the extent not obviated by the above amendments, the Section 112, first

paragraph, rejection of claims 38-60 and 63-67, is traversed. Reconsideration and

withdrawal of the rejection are requested in view of the above and the following.

The specification provides an enabling disclosure of the claimed invention. The

claims have been revised, without prejudice, to delete the objected-to recitations.

Withdrawal of the Section 112, first paragraph, rejection is requested.

The Section 112, second paragraph, rejection of claims 38-67, is obviated by the

above amendments. The Examiner's helpful suggestions are acknowledged, with

appreciation. Withdrawal of the Section 112, second paragraph, rejection is requested.
To the extent not obviated by the above amendments, the Section 103 rejection

of claims 38-40, 42, 44, 46-48, 56, 58, 63-65 and 67 over Vanstone (U.S. Patent No.

4,190,671), is traversed. Reconsideration and withdrawal of the rejection are requested

in view of the above and the following distinguishing comments.

- 18 -

1408497

NAJIB et al Appl. No. 10/520,078

Monday, November 24, 2008 Atty. Ref.: 3665-126

Atty. Ref.: 3665-

Vanstone et al. is understood to teach the use of particular compounds for

treating inflammation. The compounds of the cited art are different from the compounds

of the claims.

The applicants submit that Vanstone et al. does not belong to the same technical

field as the presently claimed invention (i.e. the treatment of a pathology related to

deregulations of lipid and/or glucose metabolism). Moreover, the cited art does not

teach or suggest or motivate one of ordinary skill in the art to modify the disclosed

compounds into compounds of the presently claimed invention, or to treat a pathology

related to deregulations of lipid and/or glucose metabolism, e.g. such as: the activation

of PPARs, particularly PPARa, or the decrease of plasma cholesterol and triglyceride

concentrations, as described in the present application.

Withdrawal of the Section 103 rejection is requested.

Reconsideration and withdrawal of the provisional Section 101 rejection of claims

38, 61 and 62 over claims 1, 5 and 10 of copending Application No. 11/493,040 is

requested as the applicants believe that the claimed inventions are not the same.

Specifically, the applicants submit that in the noted claims of the cited copending

application, the composition relates to a composition comprising compounds of formula

(I) in association with another therapeutically active ingredient. Withdrawal of the

provisional Section 101 rejection is requested.

The Examiner is requested to hold the following provisional and actual rejections

in abeyance until such time as allowable subject matter is indicated:

- 19 -

1408497

NAJIB et al Appl. No. 10/520,078 Monday, November 24, 2008 Atty. Ref.: 3665-126 AMENDMENT

the provisional Section 101 rejection of claims 38, 39, 61 and 62 over claims 69.

70, 96 and 97 of copending Application No. 10/520,079; and

the rejection of claim 38 under the judicially created doctrine of obviousness-type double patenting over claim 1 of U.S. Patent No. 7,385,082.

The claims are submitted to be in condition for allowance and a Notice or indication to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Req. No. 36,663

BJS:

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100